The Epicenter of the Specialty Pharmacy Industry
April 26 - 30, 2026 • Wynn & Encore Las Vegas

Thank you for spending time with us at Asembia 2026.

We’ve curated a selection of insights and resources exploring the key issues shaping biopharma commercialisation today. We hope these perspectives support you as you navigate an increasingly complex, competitive and fast-changing environment.

We look forward to staying in touch and continuing the conversation.

Commercial solutions for biopharma manufacturers

From the AXS26 stage: Panel Session

Navigating the CGT Commercialization Landscape: Insights from Pipeline to Patient

Cell and gene therapies are changing what’s possible for patients — and reshaping the specialty pharmacy and distribution ecosystem.

Led by Will Pih, Founder of Two Labs, this panel explored the realities of bringing CGTs from pipeline to patient, including channel model evolution, launch friction points, reimbursement and contracting, the role of value-based agreements, and how stakeholders across the healthcare ecosystem can work together to support more effective CGT commercialisation.

Continue the conversation

Two Labs and Riparian, Envision Pharma companies, partner with biopharma manufacturers across medical, market access, commercialisation and revenue management.

Our deeply experienced teams deliver customised, integrated and tech-enabled solutions to help you navigate complexity, unlock opportunities and achieve your goals.

Let’s continue the conversation about how we can best support you.